Researchers use machine learning to predict adverse events during stem cell therapy for multiple myeloma, improving outpatient safety.
Key Details
- 1Researchers analyzed data from 109 multiple myeloma patients undergoing stem cell mobilization.
- 2Machine learning models identified time periods with low risk for serious side effects during therapy.
- 3Models could accurately predict the timing and occurrence of certain side effects in individual patients.
- 4Enables more patients to safely undergo chemotherapy and stem cell mobilization as outpatients.
- 5Outpatient treatment improves quality of life and allows for better hospital resource management.
- 6Findings published in npj Digital Medicine by Göttingen and Bielefeld researchers.
Why It Matters
By accurately stratifying patient risk using AI, more multiple myeloma patients could receive therapy outside the hospital, reducing healthcare costs and improving patient experience. This study highlights the growing role for AI in personalizing oncology care pathways.
Source
EurekAlert
Related News
•EurekAlert
AI Framework Accelerates Aortic Aneurysm Risk Prediction from Imaging
Researchers developed BioPINN-LM, combining physics-informed neural networks and multimodal large language models to deliver fast, interpretable risk assessments for ascending thoracic aortic aneurysms.
•EurekAlert
Study Finds Patient Voices Missing in Generative AI Design for Oncology
A Flinders University-led review found patients and carers are rarely involved in shaping generative AI tools used in oncology.
•EurekAlert
Scripps Researchers Develop AI Foundation Model for ECG-Based Heart Disease Prediction
A new AI foundation model, ECG-CLIP, improves detection and prediction of multiple heart diseases using large-scale ECG and clinician note data.